New drug combo tested for tough-to-treat cancers
NCT ID NCT05438420
Summary
This study is testing whether adding an experimental drug called Q702 to an existing immunotherapy (pembrolizumab) is safe and effective for people with advanced esophageal, stomach, liver, or cervical cancers. The trial includes 120 participants whose cancer has continued to grow despite previous treatment with similar immunotherapies. Researchers will monitor side effects and whether tumors shrink in response to the combination treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Asan Medical Center
Seoul, South Korea
-
CHA Bundang Medical Center
Seongnam-si, South Korea
-
Norton Cancer Institute
Louisville, Kentucky, 40202, United States
-
Samsung Medical Center
Seoul, South Korea
-
Seoul National University Hospital
Seoul, South Korea
-
Severance Hospital
Seoul, South Korea
-
University of Southern California
Los Angeles, California, 90033, United States
Conditions
Explore the condition pages connected to this study.